---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-24-000192"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:51:17.011830+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa enters up to $200M loan with Oxford Finance, repays $110M Oberland debt

## Summary
- Initial $110M term loan funded; proceeds used to repay existing NPA with Oberland Capital in full.
- Additional $40M available upon clinical milestone, $50M at lenders' sole discretion; maturity Dec 2029 or Dec 2030 if milestone met.
- Interest rate floating at SOFR (floor 3.28%) + 5.00% margin; min 8.28%, max 10.50%.
- Loan secured by substantially all assets including IP; minimum cash covenant begins Oct 2026, waived if market cap ≥$1B.
- Termination of prior note purchase agreement with Oberland Capital dated Oct 2021.

## SEC filing metadata
- accession: 0001847903-24-000192
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000192/0001847903-24-000192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000192/cnta-20241230.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-24-000192
- JSON: https://secwatch.observer/filing/0001847903-24-000192.json
- Plain text: https://secwatch.observer/filing/0001847903-24-000192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.